DK1321144T3 - Øjendråber - Google Patents

Øjendråber

Info

Publication number
DK1321144T3
DK1321144T3 DK01965597.6T DK01965597T DK1321144T3 DK 1321144 T3 DK1321144 T3 DK 1321144T3 DK 01965597 T DK01965597 T DK 01965597T DK 1321144 T3 DK1321144 T3 DK 1321144T3
Authority
DK
Denmark
Prior art keywords
prostaglandin derivatives
water
liable
ophthalmic solutions
eye drops
Prior art date
Application number
DK01965597.6T
Other languages
English (en)
Inventor
Kenji Morishima
Akio Kimura
Hiroyuki Asada
Masayuki Umeda
Mitsuaki Kuwano
Original Assignee
Santen Pharmaceutical Co Ltd
Asahi Glass Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18762864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1321144(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd, Asahi Glass Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK1321144T3 publication Critical patent/DK1321144T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
DK01965597.6T 2000-09-13 2001-09-13 Øjendråber DK1321144T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000277554 2000-09-13
PCT/JP2001/007928 WO2002022131A1 (fr) 2000-09-13 2001-09-13 Collyre

Publications (1)

Publication Number Publication Date
DK1321144T3 true DK1321144T3 (da) 2011-03-07

Family

ID=18762864

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01965597.6T DK1321144T3 (da) 2000-09-13 2001-09-13 Øjendråber

Country Status (14)

Country Link
US (4) US20040097592A1 (da)
EP (1) EP1321144B1 (da)
KR (1) KR100854056B1 (da)
CN (1) CN1243548C (da)
AT (1) ATE490761T1 (da)
AU (1) AU2001286210A1 (da)
CA (1) CA2422031C (da)
CY (2) CY1113200T1 (da)
DE (1) DE60143615D1 (da)
DK (1) DK1321144T3 (da)
ES (1) ES2357551T3 (da)
NO (1) NO332650B1 (da)
PT (1) PT1321144E (da)
WO (1) WO2002022131A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097592A1 (en) * 2000-09-13 2004-05-20 Kenji Morishima Eye drops
AU2003262268A1 (en) * 2002-08-23 2004-04-30 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
ATE450264T1 (de) * 2003-07-31 2009-12-15 Santen Pharmaceutical Co Ltd Prostaglandin enthaltendes produkt
US20080139652A1 (en) 2003-11-07 2008-06-12 Yusuke Sakai Pharmaceutical Composition Containing Prostaglandin
KR101305649B1 (ko) * 2004-12-09 2013-09-09 산텐 세이야꾸 가부시키가이샤 분자 내에 불소 원자를 갖는 프로스타글란딘 함유 제품
ES2386148T3 (es) * 2004-12-24 2012-08-10 Santen Pharmaceutical Co., Ltd. Productos que contienen un derivado de prostaglandina F2 alfa
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
KR101396731B1 (ko) 2005-03-31 2014-05-19 산텐 세이야꾸 가부시키가이샤 프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
US8252945B2 (en) 2005-04-13 2012-08-28 Ube Industries, Ltd. Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient
CA2645311C (en) * 2006-03-13 2014-11-18 R-Tech Ueno, Ltd. Aqueous composition comprising 15-keto-prostaglandin for ophthalmic use
FR2912207B1 (fr) * 2007-02-01 2012-10-26 Air Liquide Procede et appareil de production de monoxyde de carbone par distillation cryogenique
JP5087448B2 (ja) * 2007-03-29 2012-12-05 参天製薬株式会社 フルオロメトロンを含有する懸濁型点眼剤
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2269612A4 (en) * 2008-04-23 2013-07-31 Otsuka Pharma Co Ltd EYE DROP PREPARATION AND ITS USE
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US20110136898A1 (en) * 2008-08-05 2011-06-09 University College Cork, National University Of Ireland, Cork Treatment of retinal degeneration
BRPI1005519A2 (pt) * 2009-02-20 2016-02-23 Micro Labs Ltd produto de prostaglandina estável ao armazenamento.
EP2269575A1 (en) 2009-06-30 2011-01-05 Santen Pharmaceutical Co., Ltd Method for improving bioavailability of latanoprost
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
ES2391721T3 (es) * 2010-03-01 2012-11-29 Laboratorios Salvat, S.A. Disoluciones acuosas transparentes de acetónido de fluocinolona para el tratamiento de la infamación de oído
EP2452669A1 (en) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
WO2013183778A1 (ja) * 2012-06-08 2013-12-12 ライオン株式会社 粘膜用組成物
CN104288092A (zh) * 2013-07-16 2015-01-21 广东东阳光药业有限公司 拉坦前列素滴眼剂
CN104622798B (zh) * 2014-12-05 2017-12-22 广东东阳光药业有限公司 一种含有他氟前列素的滴眼液及其制备方法
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
EP4285908A3 (en) 2017-03-27 2024-02-14 Alcon Inc. Pharmaceutical preparation
WO2020013717A1 (en) 2018-07-09 2020-01-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Ophthalmic dispensing device
EP3853317A4 (en) * 2018-09-21 2022-06-22 PS Therapy Ltd. ARTIFICIAL TEARS, CONTACT LENSES AND MEDICATION COMPOSITIONS AND METHODS OF USE THEREOF
JP2022512788A (ja) 2018-10-25 2022-02-07 ネクスモス カンパニー リミテッド アプタミンｃを有効成分として含む点眼液組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310543A (en) * 1980-10-09 1982-01-12 Hoffmann-La Roche Inc. Prostaglandin compositions
EP0455264B1 (en) * 1987-09-18 1994-07-13 R-Tech Ueno Ltd. Ocular hypotensive agents
JPH0662417B2 (ja) * 1987-12-25 1994-08-17 参天製薬株式会社 抗アレルギー点眼液
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5486540A (en) * 1993-10-28 1996-01-23 Allergan, Inc. Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
ATE221048T1 (de) * 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
KR20010021835A (ko) * 1998-07-14 2001-03-15 제임스 에이. 아노 프로스타글란딘 생성물
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
WO2000038663A2 (en) * 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
DK1148891T3 (da) * 1999-01-19 2004-07-26 Upjohn Co Fremgangsmåde til emballering af et oxidationsfölsomt medicinsk stof
US20040097592A1 (en) * 2000-09-13 2004-05-20 Kenji Morishima Eye drops
TW586946B (en) * 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
ATE450264T1 (de) * 2003-07-31 2009-12-15 Santen Pharmaceutical Co Ltd Prostaglandin enthaltendes produkt
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions

Also Published As

Publication number Publication date
KR100854056B1 (ko) 2008-08-26
CN1457256A (zh) 2003-11-19
KR20030029981A (ko) 2003-04-16
CA2422031C (en) 2011-11-15
DE60143615D1 (de) 2011-01-20
EP1321144B1 (en) 2010-12-08
US20070248697A1 (en) 2007-10-25
US20180353518A1 (en) 2018-12-13
PT1321144E (pt) 2011-03-10
CY2011007I2 (el) 2015-08-05
AU2001286210A1 (en) 2002-03-26
NO20031138L (no) 2003-05-12
CY1113200T1 (el) 2014-04-09
WO2002022131A1 (fr) 2002-03-21
ATE490761T1 (de) 2010-12-15
CN1243548C (zh) 2006-03-01
NO332650B1 (no) 2012-11-26
EP1321144A1 (en) 2003-06-25
US20040097592A1 (en) 2004-05-20
NO20031138D0 (no) 2003-03-12
ES2357551T3 (es) 2011-04-27
CY2011007I1 (el) 2014-04-09
CA2422031A1 (en) 2003-03-12
EP1321144A4 (en) 2009-07-29
US20160106757A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
DK1321144T3 (da) Øjendråber
CA2498233A1 (en) Clear ophthalmic solution comprising latanoprost as active ingredient
MX9101788A (es) Composiciones de tinta a base de agua
EP0766970A3 (en) Method and composition for disinfecting contact lenses
AU2001293851A1 (en) Stabilized hydrogen peroxide solutions
NO960062L (no) Farmasöytiske preparater for tungt opplöselige aktive midler
CA2124873A1 (en) Iodine-containing corrosion inhibitor for oil field acidizing operations
DE60227960D1 (de) Synergistische antimikrobielle ophthalmische zubereitungen mit chlorit- und wasserstoffperoxid
DK1273299T3 (da) Minoxidilinindeholdende praparater
ATE516016T1 (de) Selbstemulgierende formulierungen von cetp- hemmern
CO4410315A1 (es) Composicion oral que comprende cantidad efectiva de ten- sioactivo y sulfoacetato laurilo de sodio
TW266154B (da)
EP0497001A3 (en) Oxidized-type glutathione alkyl ester
AU7880794A (en) Use of phosphoric esters as crystallisation inhibitors
DE60226836D1 (de) Stabile Elektrolytlösungen enthaltend Taurolidin
KR950010911A (ko) 콘텍트 렌즈용 제제의 안정화 방법
AU2003298850A1 (en) Quaternary ammonium esters for disinfection and preservation
DE69602396D1 (de) Stabile flüssige Reinigungsmittel, die Pinienöl enthalten
ES2166306B1 (es) Composicion desinfectante tensioactiva.
AU2001242398A1 (en) Contact lens treating method and composition
BRPI0404521A (pt) Composição herbicida
JPH09251145A (ja) コンタクトレンズ用洗浄剤
RU98104644A (ru) Ингибитор коррозии нефтепромыслового оборудования